Display options
Cite
Dang HX, Krasnick BA, White BS, et al. The clonal evolution of metastatic colorectal cancer. Sci Adv. 2020;6(24):eaay9691doi: 10.1126/sciadv.aay9691.
Dang, H. X., Krasnick, B. A., White, B. S., Grossman, J. G., Strand, M. S., Zhang, J., Cabanski, C. R., Miller, C. A., Fulton, R. S., Goedegebuure, S. P., Fronick, C. C., Griffith, M., Larson, D. E., Goetz, B. D., Walker, J. R., Hawkins, W. G., Strasberg, S. M., Linehan, D. C., Lim, K. H., Lockhart, A. C., Mardis, E. R., Wilson, R. K., Ley, T. J., Maher, C. A., & Fields, R. C. (2020). The clonal evolution of metastatic colorectal cancer. Science advances, 6(24), eaay9691. https://doi.org/10.1126/sciadv.aay9691
Dang, Ha X, et al. "The clonal evolution of metastatic colorectal cancer." Science advances vol. 6,24 (2020): eaay9691. doi: https://doi.org/10.1126/sciadv.aay9691
Dang HX, Krasnick BA, White BS, Grossman JG, Strand MS, Zhang J, Cabanski CR, Miller CA, Fulton RS, Goedegebuure SP, Fronick CC, Griffith M, Larson DE, Goetz BD, Walker JR, Hawkins WG, Strasberg SM, Linehan DC, Lim KH, Lockhart AC, Mardis ER, Wilson RK, Ley TJ, Maher CA, Fields RC. The clonal evolution of metastatic colorectal cancer. Sci Adv. 2020 Jun 10;6(24):eaay9691. doi: 10.1126/sciadv.aay9691. eCollection 2020 Jun. PMID: 32577507; PMCID: PMC7286679.
Copy Download .nbib Format: NLM
Share it on

Sci Adv. 2020 Jun 10;6(24):eaay9691. doi: 10.1126/sciadv.aay9691. eCollection 2020 Jun.

The clonal evolution of metastatic colorectal cancer.

Science advances

Ha X Dang, Bradley A Krasnick, Brian S White, Julie G Grossman, Matthew S Strand, Jin Zhang, Christopher R Cabanski, Christopher A Miller, Robert S Fulton, S Peter Goedegebuure, Catrina C Fronick, Malachi Griffith, David E Larson, Brian D Goetz, Jason R Walker, William G Hawkins, Steven M Strasberg, David C Linehan, Kian H Lim, A Craig Lockhart, Elaine R Mardis, Richard K Wilson, Timothy J Ley, Christopher A Maher, Ryan C Fields

Affiliations

  1. Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
  2. McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
  3. The Alvin J. Siteman Comprehensive Cancer Center, Washington University in St. Louis, St. Louis, MO, USA.
  4. Department of Surgery, Washington University in St. Louis, St. Louis, MO, USA.
  5. Barnes-Jewish Hospital, St. Louis, MO, USA.
  6. Sage Bionetworks, Seattle, WA, USA.
  7. Department of Radiation Oncology, Washington University in St. Louis, St. Louis, MO, USA.
  8. Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  9. Department of Genetics, Washington University in St. Louis, St. Louis, MO, USA.
  10. Department of Surgery and The Wilmot Cancer Institute, University of Rochester School of Medicine, Rochester, NY, USA.
  11. Division of Medical Oncology, Department of Medicine, The Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA.
  12. Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA.
  13. Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
  14. Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, USA.

PMID: 32577507 PMCID: PMC7286679 DOI: 10.1126/sciadv.aay9691

Abstract

Tumor heterogeneity and evolution drive treatment resistance in metastatic colorectal cancer (mCRC). Patient-derived xenografts (PDXs) can model mCRC biology; however, their ability to accurately mimic human tumor heterogeneity is unclear. Current genomic studies in mCRC have limited scope and lack matched PDXs. Therefore, the landscape of tumor heterogeneity and its impact on the evolution of metastasis and PDXs remain undefined. We performed whole-genome, deep exome, and targeted validation sequencing of multiple primary regions, matched distant metastases, and PDXs from 11 patients with mCRC. We observed intricate clonal heterogeneity and evolution affecting metastasis dissemination and PDX clonal selection. Metastasis formation followed both monoclonal and polyclonal seeding models. In four cases, metastasis-seeding clones were not identified in any primary region, consistent with a metastasis-seeding-metastasis model. PDXs underrepresented the subclonal heterogeneity of parental tumors. These suggest that single sample tumor sequencing and current PDX models may be insufficient to guide precision medicine.

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

References

  1. Cell. 2014 Aug 28;158(5):1110-1122 - PubMed
  2. Science. 2017 Jul 07;357(6346):55-60 - PubMed
  3. J Clin Oncol. 2019 Feb 1;37(4):318-327 - PubMed
  4. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  5. Clin Cancer Res. 2018 May 1;24(9):2214-2224 - PubMed
  6. Sci Transl Med. 2016 Jul 6;8(346):346ra92 - PubMed
  7. Genes Dev. 2017 Feb 15;31(4):370-382 - PubMed
  8. PLoS Comput Biol. 2015 Jul 09;11(7):e1004274 - PubMed
  9. Clin Cancer Res. 2015 Jun 1;21(11):2644-51 - PubMed
  10. Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E854-63 - PubMed
  11. Clin Cancer Res. 2015 Oct 1;21(19):4461-72 - PubMed
  12. Bioinformatics. 2009 Jul 15;25(14):1754-60 - PubMed
  13. Genome Biol. 2014 Aug 28;15(8):454 - PubMed
  14. PLoS Comput Biol. 2014 Aug 07;10(8):e1003665 - PubMed
  15. Genome Biol. 2015 Feb 27;16:49 - PubMed
  16. Nat Rev Cancer. 2003 Jun;3(6):453-8 - PubMed
  17. Clin Cancer Res. 2002 Dec;8(12):3824-31 - PubMed
  18. Nature. 2010 Apr 15;464(7291):999-1005 - PubMed
  19. Ann Oncol. 2017 Sep 1;28(9):2135-2141 - PubMed
  20. Cancer Cell. 2019 Jul 8;36(1):35-50.e9 - PubMed
  21. Oncoimmunology. 2018 Aug 1;7(9):e1470729 - PubMed
  22. Nature. 2017 Sep 7;549(7670):96-100 - PubMed
  23. Cell. 1990 Jun 1;61(5):759-67 - PubMed
  24. Genes Dev. 2017 Sep 15;31(18):1827-1840 - PubMed
  25. Sci Transl Med. 2014 Feb 19;6(224):224ra24 - PubMed
  26. Nat Genet. 2019 Jul;51(7):1113-1122 - PubMed
  27. Genome Res. 2017 Aug;27(8):1287-1299 - PubMed
  28. BMC Genomics. 2016 Nov 7;17(1):880 - PubMed
  29. Nature. 2012 Jun 28;486(7404):532-6 - PubMed
  30. Cancer Res. 2010 Jul 15;70(14):5901-11 - PubMed
  31. Nature. 2012 Jul 18;487(7407):330-7 - PubMed
  32. Lancet Oncol. 2011 Jun;12(6):594-603 - PubMed
  33. Nat Rev Clin Oncol. 2019 Jul;16(7):409-424 - PubMed
  34. Nature. 2013 Oct 17;502(7471):333-339 - PubMed
  35. Ann Oncol. 2017 Dec 1;28(12):3076-3082 - PubMed
  36. Cancer Res. 2010 Jul 15;70(14):5649-69 - PubMed
  37. Nature. 2018 Apr;556(7702):457-462 - PubMed
  38. Science. 2018 Feb 23;359(6378):920-926 - PubMed
  39. Cell Syst. 2015 Sep 23;1(3):210-223 - PubMed

Publication Types

Grant support